Metabolic myopathies

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 6, 2013, Pages 1571-1597

  Tobon, Alejandro ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE; BUTYRYL COENZYME A DEHYDROGENASE; GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; LIPID; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; TRIOSEPHOSPHATE ISOMERASE;

ABNORMAL LABORATORY RESULT; BUTYRYL COENZYME A DEHYDROGENASE DEFICIENCY; CARNITINE DEFICIENCY; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CELL ENERGY; CLINICAL FEATURE; DISORDERS OF LIPID METABOLISM; ENERGY YIELD; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FAMILY HISTORY; GENETIC COUNSELING; GLYCOGEN STORAGE DISEASE TYPE 10; GLYCOGEN STORAGE DISEASE TYPE 11; GLYCOGEN STORAGE DISEASE TYPE 12; GLYCOGEN STORAGE DISEASE TYPE 13; GLYCOGEN STORAGE DISEASE TYPE 14; GLYCOGEN STORAGE DISEASE TYPE 2; GLYCOGEN STORAGE DISEASE TYPE 3; GLYCOGEN STORAGE DISEASE TYPE 4; GLYCOGEN STORAGE DISEASE TYPE 5; GLYCOGEN STORAGE DISEASE TYPE 7; GLYCOGEN STORAGE DISEASE TYPE 8; GLYCOGEN STORAGE DISEASE TYPE 9; HUMAN; KEARNS SAYRE SYNDROME; LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MELAS SYNDROME; MERRF SYNDROME; METABOLIC DISORDER; METABOLIC MYOPATHY; MITOCHONDRIAL MYOPATHY; MNGIE SYNDROME; MOLECULAR GENETICS; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; MYOPATHY; ONSET AGE; REVIEW; SYSTEMIC DISEASE; TRIOSEPHOSPHATE ISOMERASE DEFICIENCY; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY;

HUMANS; METABOLISM, INBORN ERRORS; MUSCULAR DISEASES;

EID: 84890452327     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000440660.41675.06     Document Type: Review

References (39)

1. van Adel BA, Tarnopolsky MA. Metabolic myopathies: Update 2009. J Clin Neuromuscul Dis 2009;10(3):97-121.
2. Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010;10(2):118-126.
3. Hogrel JY, Laforet P, Ben Yaou R, et al. A non-ischemic forearm exercise test for the screening of patients with exercise intolerance. Neurology 2001;56(12):1733-1738.
4. van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372(9646):1342- 1353.
5. Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 2012;160(1): 59-68.
6. Kroos M, Hoogeveen-Westerveld M, Michelakakis H, et al. Update of the pompe disease mutation database with 60 novel GAA sequence variants and additional studies on the functional effect of 34 previously reported variants. Hum Mutat 2012;33(8): 1161-1165.
7. van der Ploeg AT, Clemens PR, Corzo D, et al. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010;362(15):1396-1406.
8. Cupler EJ, Berger KI, Leshner RT, et al. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve 2012;45(3):319-333.
9. Toscano A, Schoser B. Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review. J Neurol 2013;260(4):951-959.
10. Lucchiari S, Santoro D, Pagliarani S, Comi GP. Clinical, biochemical and genetic features of glycogen debranching enzyme deficiency. Acta Myol 2007;26(1):72-74.
11. Shen J, Bao Y, Liu HM, et al. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996;98(2):352-357.
12. Bruno C, Cassandrini D, Assereto S, et al. Neuromuscular forms of glycogen branching enzyme deficiency. Acta Myol 2007;26(1): 75-78.
13. Mochel F, Schiffmann R, Steenweg ME, et al. Adult polyglucosan body disease: Natural history and key magnetic resonance imaging findings. Ann Neurol 2012;72(3):433-441.
14. Massa R, Bruno C, Martorana A, et al. Adult polyglucosan body disease: Proton magnetic resonance spectroscopy of the brain and novel mutation in the GBE1 gene. Muscle Nerve 2008;37(4):530-536.
15. Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: Controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008;12(2):137-145.
16. Vissing J, Haller RG. Mechanisms of exertional fatigue in muscle glycogenoses. Neuromuscul Disord 2012;22(suppl 3): S168YS171.
17. Nadaj-Pakleza AA, Vincitorio CM, Laforet P, et al. Permanent muscle weakness in McArdle disease. Muscle Nerve 2009;40(3): 350-357.
18. Quinlivan R, Buckley J, James M, et al. McArdle disease: A clinical review. J Neurol Neurosurg Psychiatry 2010;81(11): 1182-1188.
19. Martinuzzi A, Sartori E, Fanin M, et al. Phenotype modulators in myophosphorylase deficiency. Ann Neurol 2003;53(4):497-502.
20. Quinlivan R, Martinuzzi A, Schoser B. Pharmacological and nutritional treatment for McArdle disease (glycogen storage disease type V). Cochrane Database Syst Rev 2010;(12):CD003458.
21. Sato S, Ohi T, Nishino I, Sugie H. Confirmation of the efficacy of vitamin B6 supplementation for McArdle disease by follow-up muscle biopsy. Muscle Nerve 2012;45(3):436-440.
22. Quinlivan R, Vissing J, Hilton-Jones D, Buckley J. Physical training for McArdle disease. Cochrane Database Syst Rev 2011;(12): CD007931.
23. Musumeci O, Bruno C, Mongini T, et al. Clinical features and new molecular findings in muscle phosphofructokinase deficiency (GSD type VII). Neuromuscul Disord. 2012;22(4):325-330.
24. DiMauro S, Spiegel R. Progress and problems in muscle glycogenoses. Acta Myol 2011; 30(2):96-102.
25. Echaniz-Laguna A, Akman HO, Mohr M, et al. Muscle phosphorylase b kinase deficiency revisited. Neuromuscul Disord 2010;20(2):125-127.
26. Kraus AP, Langston MF Jr, Lynch BL. Red cell phosphoglycerate kinase deficiency. A new cause of non-spherocytic hemolytic anemia. Biochem Biophys Res Commun 1968;30(2): 173-177.
27. Salameh J, Goyal N, Choudry R, et al. Phosphoglycerate mutase deficiency with tubular aggregates in a patient from panama. Muscle Nerve 2013;47(1):138-140.
28. Serdaroglu G, Aydinok Y, Yilmaz S, et al. Triosephosphate isomerase deficiency: A patient with Val231Met mutation. Pediatr Neurol 2011;44(2):139-142.
29. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: An overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis 2012;7:68.
30. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med 2009;360(8):838-840.
31. Roe CR, Yang BZ, Brunengraber H, et al. Carnitine palmitoyltransferase II deficiency: Successful anaplerotic diet therapy. Neurology 2008;71(4):260-264.
32. Gillingham MB, Scott B, Elliott D, Harding CO. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifunctional protein (TFP) deficiency. Mol Genet Metab 2006;89(1-2):58-63.
33. Finsterer J. Inherited mitochondrial disorders. Adv Exp Med Biol 2012;942:187-213.
34. Pfeffer G, Chinnery PF. Diagnosis and treatment of mitochondrial myopathies. Ann Med 2013;45(1):4-16.
35. Davis RL, Sue CM. The genetics of mitochondrial disease. Semin Neurol 2011;31(5):519-530.
36. Goodfellow JA, Dani K, Stewart W, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes: An important cause of stroke in young people. Postgrad Med J 2012;88(1040):326-334.
37. Kerr DS. Treatment of mitochondrial electron transport chain disorders: A review of clinical trials over the past decade. Mol Genet Metab 2010;99(3):246-255.
38. Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 2011;134(pt 11):3326-3332.
39. Tang S, Dimberg EL, Milone M, Wong LJ. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: An expanded clinical spectrum of POLG1 mutations. J Neurol 2012;259(5): 862-868.